- Home
- TENX
as 11-15-2024 9:48am EST
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.
| Founded: | 1967 | Country: | United States |
| Employees: | N/A | City: | CHAPEL HILL |
| Market Cap: | 11.4M | IPO Year: | N/A |
| Target Price: | $20.67 | AVG Volume (30 days): | 96.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.32 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.77 - $41.92 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Tenax Therapeutics Inc. News
TENX Breaking Stock News: Dive into TENX Ticker-Specific Updates for Smart Investing
Associated Press Finance
2 days ago
Tenax Therapeutics: Q3 Earnings Snapshot
GlobeNewswire
2 days ago
Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
GlobeNewswire
15 days ago
Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference
Zacks Small Cap Research
3 months ago
TENX: $100 Million Capital Raise
Associated Press Finance
3 months ago
Tenax Therapeutics: Q2 Earnings Snapshot
GlobeNewswire
3 months ago
Tenax Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
MT Newswires
3 months ago
Tenax Therapeutics Raises $100 Million From Private Placement
GlobeNewswire
3 months ago
Tenax Therapeutics Announces Closing of $100 Million Private Placement and Plans to Accelerate the Oral Levosimendan Phase 3 Program
Compare TENX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TENX Tenax Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.